Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | KDM1A | O60341 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | PAK4 | O96013 | 3/20 | 0.39 |
| ▸ | TLR2 | O60603 | 3/20 | 0.37 |
| ▸ | TLR1 | Q15399 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25304830 | 0.86 | CA1 (0.48) | CA1CA2CA9EPHX2MAOA | |
| SCHEMBL25297036 | 0.85 | CA1 (0.56) | CA1CA2CA9EPHX2MAOA | |
| SCHEMBL25613761 | 0.83 | EPHX2 (0.41) | EPHX2 | |
| SCHEMBL30398988 | 0.83 | EPHX2 (0.41) | EPHX2 | |
| SCHEMBL25304538 | 0.83 | EPHX2 (0.50) | CA1CA2CA9EPHX2MAOA | |
| SCHEMBL30399042 | 0.82 | GCG (0.37) | — | |
| SCHEMBL25613749 | 0.82 | GCG (0.37) | — | |
| SCHEMBL25303126 | 0.82 | EPHX1 (0.38) | — | |
| SCHEMBL25303130 | 0.82 | EPHX1 (0.38) | — | |
| SCHEMBL25297058 | 0.81 | PAK4 (0.38) | EPHX2MAOAKDM1AMAOBPAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4452944-A1 | CYCLOPROPYL COMPOUNDS | Icagen, LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240336571-A1 | NOVEL CYCLOPROPYL COMPOUNDS | ANGELINI PHARMA S.P.A. (IT) | 2024-10-10 | — | — | US | disclosed |
| WO-2023121992-A1 | CYCLOPROPYL COMPOUNDS | ICAGEN, LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023121992-A1 | CYCLOPROPYL COMPOUNDS | ICAGEN, LLC (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336571-A1 | NOVEL CYCLOPROPYL COMPOUNDS | C1R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CNR1 | CA1 2344/4885CA2 1504/4885CA9 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.